TrialBlood2018

RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature.

Michael A Chapman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.